Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4697050 | 0.79 | ALDH1A1 (0.36) | CYP3A4 | |
| SCHEMBL1197431 | 0.78 | ACHE (0.32) | CYP3A4ACHE | |
| SCHEMBL909850 | 0.78 | LMNA (0.38) | CLCN2CYP3A4 | |
| SCHEMBL7703149 | 0.74 | CES2 (0.31) | — | |
| SCHEMBL2578269 | 0.72 | ACHE (0.38) | P2RX7ADRA2ACLCN2CYP3A4ACHE | |
| SCHEMBL28566856 | 0.71 | GABRA1 (0.40) | CYP3A4 | |
| SCHEMBL10595967 | 0.70 | ACHE (0.36) | P2RX7ADRA2ACLCN2CYP3A4ACHE | |
| SCHEMBL8249627 | 0.70 | ACHE (0.36) | P2RX7ADRA2ACLCN2CYP3A4ACHE | |
| SCHEMBL9712454 | 0.70 | SLC2A1 (0.35) | — | |
| SCHEMBL21201458 | 0.70 | TNF (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | GRUENENTHAL GMBH (DE) | 2013-09-05 | — | — | US | disclosed |
| EP-1654253-B1 | SUBSTITUTED 3-PYRROLIDIN-INDOLE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2007-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231327-A1 | Substituted Spiro-Amide Compounds | BDKRB1, BDKRB2, REN | P2RX7 314/4885ADRA2A 201/4885CLCN2 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.